Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor

Refractoriness to growth factor therapy is commonly associated with inferior outcome in patients with low-risk myelodysplastic syndrome (LR-MDS) who require treatment for cytopenias. However, the mechanisms leading to refractoriness are unknown. Here we describe a clinically depressed 74-year-old ma...

Full description

Bibliographic Details
Main Authors: Kirtan Nautiyal, Rui Li, Sarvari Yellapragada, Perumal Thiagarajan, Martha Mims, Gustavo Rivero
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Leukemia Research Reports
Subjects:
Myelodysplasia
Transfusion dependence
Erythropoietin
Sertraline
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048914000223

Internet

http://www.sciencedirect.com/science/article/pii/S2213048914000223

Similar Items